BioCryst Presents New HAE Data for ORLADEYO® and Navenibart at EAACI 2026

BioCryst to Present New HAE Data from ORLADEYO® and Navenibart at EAACI 2026

BioCryst Pharmaceuticals will present new hereditary angioedema (HAE) data for its oral therapy ORLADEYO® (berotralstat) and its investigational therapy navenibart at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting. The presentation highlights BioCryst's ongoing commitment to advancing HAE treatment. For BD teams and investors tracking the HAE space, the EAACI readout serves as a near-term catalyst with direct implications for the commercial franchise and pipeline valuation.

Key Takeaways

• BioCryst announced on May 27, 2026, that it will present new HAE data at the 2026 EAACI Annual Meeting, covering both ORLADEYO® (berotralstat) and the investigational asset navenibart.
• ORLADEYO® is the first and only oral therapy designed specifically to prevent HAE attacks in adults and children as young as two, and new data could reinforce its competitive positioning against injectable prophylactics.
• Navenibart data will offer an early look at BioCryst's next-generation HAE pipeline candidate, a critical element for analysts modeling long-term revenue beyond the current ORLADEYO® franchise.
• The presentation follows a busy conference season for BioCryst, which presented nine HAE abstracts at the 2026 AAAAI Annual Meeting in February, signaling an aggressive data-generation strategy.
• EAACI 2026 provides a European-stage opportunity to reach key opinion leaders and potential commercial partners in a region where HAE diagnosis rates and treatment access are expanding.

What Does the BioCryst Press Release Reveal About the EAACI 2026 Presentation?

The BioCryst press release, issued on May 27, 2026, from the company's headquarters in Research Triangle Park, North Carolina, confirmed that the EAACI presentation will include data on ORLADEYO® (berotralstat) and navenibart. The release did not disclose specific efficacy endpoints, patient population details, or the format of the presentations (poster versus oral session), leaving the clinical community and investors awaiting the actual congress disclosures.

What the press release does confirm is strategic intent. By pairing an approved commercial asset with an investigational program at a single major congress, BioCryst is signaling to the HAE specialist community that its pipeline extends well beyond the current ORLADEYO® franchise. For competitive intelligence teams at rival companies, the dual-asset presentation warrants close attention — it suggests BioCryst is building a layered defense of its oral prophylaxis positioning while seeding awareness of its next-generation candidate.

How Does ORLADEYO® Fit Into the Current HAE Prophylaxis Market?

ORLADEYO® holds a distinct position in the HAE market as the first and only targeted oral prophylactic therapy for patients aged two and older. The capsule formulation received FDA approval in December 2020 for patients 12 years and older, with subsequent expansion into younger pediatric populations. The therapy works by inhibiting plasma kallikrein, reducing the production of bradykinin that drives angioedema attacks.

The competitive set for HAE prophylaxis includes Takeda's TAKHZYRO® (lanadelumab), a monoclonal antibody administered subcutaneously every two to four weeks, and CSL Behring's Haegarda® (C1 esterase inhibitor), a twice-weekly subcutaneous infusion. KalVista Pharmaceuticals' sebetralstat, an oral on-demand therapy, addresses the acute treatment space rather than prevention. ORLADEYO® occupies the oral prophylaxis niche largely on its own, and BioCryst has been working to deepen that moat through pediatric data, real-world evidence, and health economics outcomes research.

Any new efficacy, safety, or real-world outcomes data presented at EAACI could support label expansion discussions, formulary negotiations, or head-to-head positioning against these injectable options. For BD teams evaluating licensing or co-promotion opportunities, the European data package could be a deciding factor in markets where ORLADEYO® penetration remains early.

What Is Known About Navenibart and Why Does It Matter?

Navenibart represents the more speculative element of the EAACI presentation. BioCryst has not yet publicly disclosed the mechanism of action or clinical-stage details for navenibart in the available press materials. However, its inclusion alongside ORLADEYO® at a major international congress suggests the company views it as a material pipeline asset worthy of early-stage visibility with the specialist community.

For analysts covering BCRX, any Phase I pharmacokinetic or efficacy signals on navenibart will feed directly into long-term revenue models and partnership probability assessments. BioCryst's market capitalization remains heavily tied to ORLADEYO® revenue trajectory, and investors have been looking for evidence that the company can build a next-generation franchise. A credible pipeline candidate — particularly one with a differentiated mechanism or dosing advantage — would reframe the growth narrative considerably.

The HAE pipeline has seen increased activity in recent years, with multiple companies pursuing oral and injectable approaches to both prophylaxis and acute treatment. BioCryst's decision to present navenibart data at EAACI, rather than waiting for a larger or more specialized venue, may indicate that the company has data it considers compelling enough to share with a broad allergy and immunology audience — or that it wants to establish priority claims in a competitive development space.

Why Is EAACI 2026 Strategically Important for BioCryst?

Presenting at EAACI matters because European treatment guidelines and reimbursement pathways for HAE differ materially from the US. The European Academy of Allergy and Clinical Immunology's guidelines carry weight with national health technology assessment bodies, and KOL engagement at this meeting can accelerate adoption in markets where ORLADEYO® uptake is still building.

The European HAE market represents a significant growth opportunity. Diagnosis rates in many EU member states remain below those in the US, meaning there is a larger pool of untreated or undertreated patients. Real-world data showing ORLADEYO®'s effectiveness in diverse European clinical practice settings could help BioCryst and its potential commercial partners make the case for broader reimbursement.

For navenibart, the European stage offers a chance to gauge KOL receptivity to a new mechanism or dosing paradigm before committing to larger pivotal trial investments. Early feedback from EAACI attendees could shape the clinical development program's design and endpoint selection.

How Does This Fit Into BioCryst's Broader Conference Strategy?

The EAACI presentation is not an isolated event. In February 2026, BioCryst presented nine abstracts from its HAE portfolio at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, including six featuring new clinical trial and real-world outcomes data with ORLADEYO®. The company's investor relations page confirmed the AAAAI presentations covered data in patients as young as two years old.

Back-to-back major congress presentations suggest BioCryst is executing a deliberate strategy to saturate the clinical conversation with ORLADEYO® data while simultaneously introducing navenibart to the specialist community. For competitive intelligence teams at rival HAE-focused companies, the volume and cadence of these presentations signal that BioCryst is not defending its position but actively expanding the evidence base.

The company's investor relations page has maintained a steady cadence of press releases around these conference presentations, providing a paper trail for analysts tracking the company's data-generation momentum.

What Should Investors and Analysts Watch Next?

The immediate catalyst is the EAACI presentation itself, where the specific data points — attack rate reductions, quality-of-life metrics, subgroup analyses, and any navenibart pharmacokinetic or efficacy signals — will drive near-term analyst commentary and potential stock movement. Beyond the conference, the key milestones to track include any regulatory filings related to expanded ORLADEYO® indications, updates on navenibart's clinical development timeline, and quarterly earnings commentary on ORLADEYO® prescription trends.

BioCryst's next earnings call will likely include management commentary on the EAACI data reception and any implications for guidance. The company's SEC filings and investor relations materials remain the primary sources for financial updates. Investors should also monitor ClinicalTrials.gov for any new study registrations related to navenibart, which would signal progression into later-stage development.

Frequently Asked Questions

Related profiles

• ORLADEYO
• Biocryst

Related coverage

• Ascentage Pharma's Olverembatinib Update: Insights from ASCO 2026
• Cancer Therapy OST-HER2 Faces 2026 EMA Call After Survival Data
• Insights from ESMO Asia: Nadia Harbeck on Oncology Advances